Median effective dosage of constant rate infusion of Ciprofol combined with different doses of esketamine during gastrointestinal endoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093995

Enrollment

Unknown

Registered

2024-12-16

Start date

2024-12-16

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group1:esketamine 0.25 mg/kg

Experimental group 2:esketamine 0.5 mg/kg

Control group:normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. ASA classification is I-III; 3. Body mass index (BMI) 19–27 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. The patient is allergic to either Ciprofol or esketamine ; 2. Long-term use of painkillers; 3. Alcoholism; 4. Nervous system or schizophrenia; 5. Advanced liver or kidney disease; 6. Sleep apnea syndrome; 7. Uncontrolled hypertension, blood pressure higher than 180/120mmHg; 8. Psychotropic drug users.

Design outcomes

Primary

Measure	Time frame
Blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactSong jinchao

Shidong Hospital, Yangpu District, Shanghai

sjcho2013@163.com+86 21 2506 6782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026